Dr. Pagadala was awarded his Ph.D. in 2007 from the department of genetics at Osmania University, Hyderabad. He worked as a postdoctoral fellow at Katholike University, Leuven, Belgium and then as an assistant professor, in the Department of Biotechnology, Srikrishna Devaraya University, Anantapur, India. As a postdoc at the University of Alberta, he worked on ligand interactions with the prion protein which has led to new insights into the understanding of folding and aggregation of prion proteins into amyloid fibrils, development of new antiprion compounds and new lead compounds which will bind to the specific binding pockets and inhibit prion protein conversion and aggregation and understanding aggregation mechanisms at the atomic level for other neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.
Now a research associate at the UofA, he has been focusing on rational and computational drug design against bacterial toxins and viral targets, computational modelling of ion channels and cardiotoxicity prediction, as well as protein-protein interactions, RNA binding and vaccine development for Hepatitis C Virus. He has published 21 international papers in peer reviewed journals so far in the area of genomics, molecular modeling and computer aided drug design. His research plans focus on the opportunities at the intersection of computation and biology. In particular, he is interested in design of the drugs for various pathological diseases where 90% of potentially efficacious compounds failing at latter stages and continuing to apply computational drug discovery to pressing scientiﬁc problems.